Human metabolism of [14C]indisulam following i.v. infusion in cancer patients
- 76 Downloads
Indisulam is a new anticancer drug with a unique mechanism of action, arresting the cell cycle at the G1/S transition. The major excretory pathway of indisulam is via the urine, accounting for 63% of the radioactive dose ([14C]indisulam) administered in a human mass balance study. Radiochromatographic profiling of urine samples resulted in the detection of several radioactive peaks. The purpose of the present investigation was to elucidate the chemical structures of these observed indisulam metabolites. We collected fractions after chromatographic separation of the urine samples. These fractions were analysed using tandem mass spectrometry. We propose the chemical structure of 15 indisulam metabolites in urine. The metabolism of indisulam is very complex, consisting of oxidative dechlorination, hydroxylation, hydrolysis, acetylation, sulphation and glucuronidation. The clinical relevance of the observed indisulam metabolites needs further investigation.
Keywordsmetabolism indisulam pharmacokinetics anticancer radiochromatography
Unable to display preview. Download preview PDF.
- 3.Van Kesteren C, Beijnen JH, Schellens JHM: E7070: A novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anticancer Drugs 13: 989–997, 2002Google Scholar
- 5.Yokoi A, Kuromitsu J, Kawai T, Nagasu T, Sugi NH, Yoshimatsu K, Yoshino H, Owa T: Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol Cancer Ther 1: 275–286, 2002Google Scholar
- 7.Van den Bongard HJGD, Pluim D, Rosing H, Nan-Offeringa L, Schot M, Ravic M, Schellens JHM, Beijnen JH: An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anticancer Drugs 13: 807–814, 2002Google Scholar
- 18.Barrientos-Astigarraga RE, Vannuchi YB, Sucupira M, Moreno RA, Muscara MN, De Nucci G: Quantification of nimesulide in human plasma by high-performance liquid chromatography/tandem mass spectrometry. Application to bioequivalence studies. J Mass Spectrom 36: 1281–1286, 2001CrossRefPubMedGoogle Scholar
- 19.Crommentuyn KM, Rosing H, Hillebrand MJ, Huitema AD, Beijnen JH: Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 804: 359–367, 2004PubMedGoogle Scholar
- 21.Rowland M, Tozer TN: Clinical Pharmacokinetics—Concepts and Applications. Williams & Wilkins, 1995Google Scholar
- 22.Van Kesteren C, Mathot RA, Raymond E, Armand JP, Dittrich C, Dumez H, Roche H, Droz JP, Punt C, Ravic M, Wanders J, Beijnen JH, Fumoleau P, Schellens JHM: Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: Model building and validation. J Clin Oncol 20: 4065–4073, 2002Google Scholar